Icon (NASDAQ:ICLR) reported third-quarter 2026 results that management said were in line with expectations, citing record net business wins, improving margins and continued investment in technology-enabled clinical development services.
Revenue was just over $2 billion, down 2.9% from a year earlier and 2.5% on a constant-currency basis, according to CFO Nigel Clerkin. Sequential revenue declined 1.9%, primarily reflecting the divestiture of Symphony. Adjusted EBITDA rose 3% sequentially to $337 million, while adjusted EBITDA margin expanded 70 basis points to 16.6%.
Adjusted net income totaled $206 million, or $2.66 per share, representing a 4% sequential increase in adjusted EPS. On a GAAP basis, income from operations was $199 million, or 10% of revenue, while net income was $122 million, or $1.58 per diluted share.
Bookings reach record level
CEO Barry Balfe said gross business wins increased 27% year over year and 3% sequentially. Net business wins reached a record $3.15 billion, up 51% from the prior-year period, producing a net book-to-bill ratio of 1.56x. It was the company’s fourth consecutive quarter with net book-to-bill above 1.3x.
Balfe said trailing 12-month direct-fee book-to-bill was 1.3x, approximately 30% higher than in the preceding 12-month period. He said direct-fee revenue returned to modest sequential growth during the quarter, characterizing that development as an “important milestone.”
Management attributed commercial momentum to demand from large pharmaceutical companies, mid-size drugmakers and biotechnology customers. Large-pharma activity included full-service and functional service provider, or FSP, work, plus an expanded alliance that added a large-scale pharmacovigilance portfolio. The company also cited multi-year FSP renewals.
In biotechnology, Balfe said the company expanded its target universe and was covering 30% more companies than one year earlier. Icon added three preferred partnerships with enterprise biotech customers during the quarter, including a four-year sole-provider arrangement spanning all phases of development.
Margins, costs and technology investments
Adjusted gross margin was 24.7%, up 90 basis points from the second quarter. Clerkin attributed the improvement to business mix and operating cost management. Adjusted selling, general and administrative expense was $163 million, or 8.1% of revenue, compared with $179 million, or 8.6% of revenue, in the third quarter of 2025.
Management said recently awarded business has begun to convert into revenue and that the company expects operating leverage as direct-fee activity develops. However, executives did not issue formal 2027 guidance. Balfe said that, with execution, mid-single-digit revenue expansion and higher-single-digit earnings growth next year were reasonable possibilities, while emphasizing that the company would provide formal guidance with fourth-quarter results.
The company also highlighted technology and artificial intelligence initiatives. Balfe said SDTM programming agents in production since February reduced programming cycle times by 28% on in-scope studies. Study-startup throughput increased about 30% year to date, aided by agentic capabilities, he said. Icon’s SmartDraft tool helped reduce site-contracting cycle times by 10% over the year, with a near-term goal for an additional 20% reduction.
Balfe said customer discussions are increasingly focused on expertise, outcomes, speed, cost and predictability rather than solely on labor rates. He said the company seeks to structure certain relationships around productivity improvements and gain-sharing, particularly in alliance and preferred-partnership settings.
Cash flow, debt refinancing and buybacks
Cash from operating activities was $340 million in the third quarter, and capital expenditures were $38 million, producing free cash flow of $302 million. The company ended the quarter with $809 million in cash and net debt of $2.6 billion, compared with $2.5 billion at the end of the second quarter and $2.9 billion a year earlier.
During the quarter, Icon completed a $2.15 billion investment-grade bond issuance. The proceeds were used to repay the company’s senior secured term loan, redeem notes due in May 2027 and repay a bridge secured credit facility. Clerkin said total debt of $3.4 billion now carries blended annual fixed interest expense of approximately $200 million. The company’s leverage ratio was 2.0 times net debt to adjusted trailing-12-month EBITDA at Sept. 30.
Icon repurchased $400 million of shares during the quarter at an average price of $170 per share. Its board also authorized a new $750 million share repurchase program. Balfe said the company’s capital-allocation priorities include organic investment, selective acquisitions and shareholder returns, but added that Icon was not pursuing transformational M&A merely to increase scale.
Updated outlook
Management narrowed its 2026 guidance range, saying the change reflects greater visibility into fourth-quarter revenue and earnings trends. Clerkin said revenue guidance was raised to the high end of the company’s previous range because pass-through activity is now expected to exceed its prior assumption of being roughly flat year over year.
Pass-through revenue was in the low 30% range as a share of total revenue, approaching one-third, Clerkin said. He added that the company remains on track for full-year adjusted EBITDA margin of approximately 16% to 16.5%, depending in part on fourth-quarter pass-through activity.
Management expects the 2026 adjusted effective tax rate to be about 17% because of fourth-quarter timing benefits, followed by an approximately 18% rate in 2027. Third-quarter adjusted net interest expense was $43 million, compared with $47 million in the prior-year period.
About Icon (NASDAQ:ICLR)
ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.
Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.
